Integra Lifesciences Holdings (IART) Common Equity (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Common Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 31.61% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 31.61% YoY), and the FY2025 full-year result was $1.0 billion, down 32.47% from the prior year.
• Common Equity held at $1.0 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
• A 5-year average of $1.5 billion and a median of $1.6 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity climbed 7.1% in 2022 and slumped 32.47% in 2025, its largest moves.
• Tracing IART's Common Equity over 5 years: stood at $1.8 billion in 2022, then dropped by 12.0% to $1.6 billion in 2023, then decreased by 2.68% to $1.5 billion in 2024, then tumbled by 32.47% to $1.0 billion in 2025, then declined by 0.1% to $1.0 billion in 2026.
• Business Quant data shows IART's Common Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.